Itacitinib + Immune effector cell therapy + Placebo + Yescarta
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cytokine Release Syndrome
Conditions
Cytokine Release Syndrome
Trial Timeline
Feb 7, 2020 → Aug 22, 2023
NCT ID
NCT04071366About Itacitinib + Immune effector cell therapy + Placebo + Yescarta
Itacitinib + Immune effector cell therapy + Placebo + Yescarta is a phase 2 stage product being developed by Incyte for Cytokine Release Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04071366. Target conditions include Cytokine Release Syndrome.
What happened to similar drugs?
0 of 2 similar drugs in Cytokine Release Syndrome were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04071366 | Phase 2 | Completed |
Competing Products
3 competing products in Cytokine Release Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Canakinumab + Placebo | Novartis | Phase 3 | 40 |
| canakinumab | Novartis | Pre-clinical | 26 |
| Ruxolitinib + Placebo | Novartis | Phase 3 | 40 |